Fmr LLC Adagene Inc. Transaction History

Fmr LLC

$1.68 Trillion
Q2 2025

A detailed history of Fmr LLC transactions in Adagene Inc. stock. As of the latest transaction made, Fmr LLC holds 379,159 shares of ADAG stock, worth $690,069. This represents 0.0% of its overall portfolio holdings.

Number of Shares

379,159

Previous 1,181,635 67.91%

Holding current value

$690,069

Previous $1.8 Million 58.85%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$1.39 - $2.09 $1.12 Million - $1.68 Million	-802,476 Reduced 67.91%	379,159 $739,000
Q1 2025 May 12, 2025	SELL	$1.52 - $2.1 $165,322 - $228,406	-108,765 Reduced 8.43%	1,181,635 $1.8 Million
Q3 2024 Nov 13, 2024	SELL	$2.12 - $3.49 $85,378 - $140,552	-40,273 Reduced 3.03%	1,290,400 $2.86 Million
Q2 2024 Aug 13, 2024	SELL	$2.12 - $3.24 $38,821 - $59,330	-18,312 Reduced 1.36%	1,330,673 $4.07 Million
Q1 2024 May 13, 2024	BUY	$1.96 - $4.15 $2.4 Million - $5.08 Million	1,224,023 Added 979.52%	1,348,985 $3.78 Million
Q4 2023 Feb 13, 2024	SELL	$1.31 - $1.93 $1.31 Million - $1.93 Million	-1,000,000 Reduced 88.89%	124,962 $241,000
Q2 2022 Aug 12, 2022	SELL	$1.99 - $3.85 $225,289 - $435,862	-113,211 Reduced 9.14%	1,124,962 $2.26 Million
Q1 2022 May 13, 2022	SELL	$3.5 - $8.79 $52,122 - $130,900	-14,892 Reduced 1.19%	1,238,173 $4.42 Million
Q4 2021 Feb 14, 2022	SELL	$7.4 - $14.44 $13,675 - $26,685	-1,848 Reduced 0.15%	1,253,065 $10 Million
Q3 2021 Nov 15, 2021	BUY	$12.7 - $20.68 $15.9 Million - $26 Million	1,254,913 New	1,254,913 $18 Million

Others Institutions Holding ADAG

# of Institutions

Shares Held

9.67M

Call Options Held

Put Options Held

View Full List

About Adagene Inc.

Ticker ADAG
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,423,200
Market Cap $79M
Description
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid ...

More about ADAG

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Fmr LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fmr LLC with notifications on news.

Account